Novavax Inc vs SOLAI Limited — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Novavax Inc is far larger — about 77.9× SOLAI Limited's market cap, and Novavax Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| NVAX | SLAI | |
|---|---|---|
Market Cap | $1.30B | $16.69M |
Sector | Health | Technology |
52-Week High | $11.19 | $26.74 |
52-Week Low | $6.22 | $2.74 |
Enterprise Value | $800.50M | $16.33M |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →